TARGET AUDIENCE
This activity is intended for medical oncologists, hematologist-oncologists and other healthcare providers involved in the treatment of hepatocellular carcinoma (HCC).

OVERVIEW OF ACTIVITY
HCC, the most common form of liver cancer, is the third leading cause of cancer-related deaths worldwide, and the rising incidence, multiple etiologies, genetic heterogeneity and concurrent chronic liver disease make the selection of treatment options for this disease challenging. In addition, HCC is often diagnosed in the advanced stage and is then associated with poor prognosis. Recent breakthroughs in understanding the etiology and pathogenesis of HCC have led to the discovery and subsequent FDA approvals of an array of novel therapies. In order to offer optimal patient care for this commonly encountered condition and appropriately integrate new agents into practice, the practicing oncologist must be well informed of these advances.

To bridge the gap between research and patient care, this issue of Hepatocellular Carcinoma Update uses one-on-one discussions with leading gastrointestinal oncology investigators. By providing access to the latest research developments and expert perspectives on HCC, this CME program will assist medical oncologists and select gastroenterology specialists in the formulation of up-to-date clinical management strategies.

LEARNING OBJECTIVES

• Consider patient age, performance status, liver function and other clinical and disease-specific factors in the development of evidence-based strategies for the management of advanced HCC.
• Understand the scientific rationale for and recall available clinical data with approved and investigational immune checkpoint inhibitors, alone and in combination with targeted agents, in the treatment of HCC.
• Appraise available data with and consider the clinical role of agents targeting angiogenesis in the treatment of HCC.
• Counsel patients regarding the incidence and manifestation of side effects and toxicities associated with existing and emerging targeted agents and immunotherapeutic approaches in the management of advanced HCC.
• Recall available and emerging data with investigational agents and strategies currently in clinical testing for HCC.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
CME credit is no longer available for this issue

HOW TO USE THESE CME ACTIVITIES
This CME activity consists of an audio component.
CME credit is no longer available for this issue

This CME activity consists of a video component.
CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

James J Harding, MD
Assistant Attending
Gastrointestinal Oncology Service
Early Drug Development Service
Memorial Sloan Kettering Cancer Center
New York, New York

Consulting Agreements: Bristol-Myers Squibb Company, CytomX Therapeutics, Eisai Inc, Exelixis Inc, Imvax, Lilly, Merck; Contracted Research: Bristol-Myers Squibb Company; Data and Safety Monitoring Board/Committee: Merck.

Tim Greten, MD
Bethesda, Maryland

No financial interests or affiliations to disclose.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Bristol-Myers Squibb Company, Eisai Inc and Merck.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
Adobe Flash Player 27 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Release date: April 2020
Expiration date: April 2021